A simplified combination antiretroviral therapy regimen enhances adherence, treatment satisfaction and quality of life: Results of a randomized clinical trial

HIV Medicine

Volumn 15, Issue 5, 2014, Pages 286-290

  Langebeek, N ^a   Sprenger, H G ^b   Gisolf, E H ^a   Reiss, P ^c   Sprangers, M A G ^c   Legrand, J C ^d   Richter, C ^a   Nieuwkerk, P T ^c  

^a RIJNSTATE HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Teaching Hospital of Charleroi   (Belgium)

Author keywords

Adherence; Antiretroviral therapy; Compliance; Quality of life; Randomized controlled trial; Simplified regimen; Treatment satisfaction

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR;

ADULT; ARTICLE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; NUTRITIONAL REQUIREMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADHERENCE; ANTIRETROVIRAL THERAPY; COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIMPLIFIED REGIMEN; TREATMENT SATISFACTION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BELGIUM; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; LOPINAVIR; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PATIENT SATISFACTION; QUALITY OF LIFE; RITONAVIR; ZIDOVUDINE;

EID: 84897414983     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12112     Document Type: Article

References (15)

1. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplify for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004; 36: 808-816.
2. Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus more frequent regimen improves daherence while maintaining viral suppression. HIV Clin Trials 2008; 9: 164-176.
3. Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ. Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med 2008; 9: 667-672.
4. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clinical. Infect Dis 2009; 48: 484-488.
5. Wright D, Rodriquez A, Godofsky E etal. Efficacy and safety of 48 weeks of effuvirtide 180mg once-daily dosing versus 90mg twice-daily dosing in HIV-infected patients. HIV Clin Trials 2008; 9: 73-82.
6. Zajenverg R, Podsadecki T, Badal-Faesen S etal. Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1 infected subjects at 48 weeks. J Acquir Immune Defic Syndr 2010; 54: 143-151.
7. Airoldi M, Zaccarelli M, Bisi L etal. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient 2010; 4: 115-125.
8. Gianotti N, Galli L, Bocchiola B etal. Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy. HIV Med 2013; 14: 153-160.
9. Sprenger HG, Langebeek N, Mulder PH etal. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naive patients: FREE randomized trial interim results. AIDS Patient Care STDS 2010; 24: 361-366.
10. Knobel H, Alonso J, Casado JL etal. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA study. AIDS 2002; 16: 605-613.
11. Woodcock A, Bradley C. Validation of the revised 10-item HIV treatment satisfaction questionnaire status version and new change version. Value Health 2006; 9: 320-333.
12. Revicki DA, Sorensen S, Wu AW. Reliability and validity of physical and mental health summary scores from the Medical Outcome Study HIV Health Survey. Med Care 1998; 36: 126-137.
13. Katlama C, Fenske S, Gazzard B etal. TRIZAL study: switching from successful HAART to Trizivir (abacvir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003; 4: 79-86.
14. Markowitz M, Hill-Zabala C, Lang J etal. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48 weeks maintenance with abacavir/lamivudine/zidovudine alone in antiretriviral -naive HIV-1 infected patients. J Acquir Immune Defic Syndr 2005; 39: 257-263.
15. Clotet B, Carmena J, Pulido F, Luque I, Rodriquez-Alcanatara F. Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral experienced patients. HIV Clin Trials 2004; 5: 33-39.